Power Stick Deodorant Recall: How to return and get refund? See product types, quantities, affected lot numbers, fda report, recall reason, retail stores
The recall was announced by the US Food and Drug Administration (FDA) after the company reported deviations from current Good Manufacturing Practices (cGMP). The affected products were sold at major retailers including Walmart, Dollar Tree and Amazon.
Power Stick Deodorant Recall Types and Quantities
The recall includes three types of Power Stick roll-on antiperspirant deodorants.
Explore courses from Top Institutes in
Select a Course Category
Management
Artificial Intelligence
Public Policy
Degree
Project Management
Data Science
healthcare
Others
Finance
Digital Marketing
Operations Management
Leadership
Healthcare
MBA
CXO
others
PGDM
Design Thinking
Technology
Data Science
Data Analytics
Product Management
MCA
Cybersecurity
Skills you'll gain:
Duration:
9 Months
IIM Calcutta
CERT-IIMC APSPM India
Starts on
undefined
Get Details
Skills you'll gain:
Duration:
10 Months
IIM Kozhikode
CERT-IIMK GMPBE India
Starts on
undefined
Get Details
Skills you'll gain:
Duration:
11 Months
IIM Kozhikode
CERT-IIMK General Management Programme India
Starts on
undefined
Get Details
Power Stick for Her Roll-On Antiperspirant Deodorant Powder Fresh (1.8 oz/53 mL): 21,265 cases
Power Stick Invisible Protection Roll-On Antiperspirant Deodorant Spring Fresh (1.8 oz/53 mL): 22,482 cases
Power Stick Original Nourishing Invisible Protection Roll-On Antiperspirant Deodorant (1.8 oz/53 mL): 23,467 cases
Power Stick Deodorant Recall Affected Lot Numbers
Power Stick for Her Roll-On Antiperspirant Deodorant Powder Fresh:
032026B011
032226B031
051626C241
061526C882
071226D371
071226D381
082526E341
082826E402
Power Stick Invisible Protection Roll-On Antiperspirant Deodorant Spring Fresh:
031726A991
041226B561
062026C901
062026C911
071026D351
071026D361
071326D391
111626G231
Live Events
Power Stick Original Nourishing Invisible Protection Roll-On Antiperspirant Deodorant:
101225D781
032926B281
032826B221
041126B531
062226D011
070626D301
070626D333
111026G051
111326G091
111626G221
Power Stick Deodorant Recall FDA Report and Recall Reason
The recall was listed in an FDA enforcement report. It noted the reason for the recall as 'cGMP deviations.' This means the products were made outside the standards outlined by the FDA's Current Good Manufacturing Practice regulations. The recall was initiated on July 10, 2025.
Also Read:
Who fired Maurene Comey and Why? See ex-FBI Director daughter's high profile cases and what happened on day of departure
Which Stores Sold These Products?
The deodorants were shipped across the United States. They were available for purchase at Walmart, Dollar Tree and on Amazon. The products were manufactured at A.P. Deauville's factory in Pennsylvania, which the company says is FDA-regulated.
Company Background and Additional Products
A.P. Deauville is based in Easton, Pennsylvania. The company manufactures personal care products including shampoos, conditioners, body washes, lotions and facial wipes. It reported the issue voluntarily to the FDA and initiated the recall process.
Also Read:
Tomorrowland 2025: Will festival go as planned? See organizers statement, event schedule, venue, expected visitors and full list of performers
How to Return and Get Refund?
Consumers who have purchased any of the affected Power Stick deodorant products are advised to stop using them immediately. They should contact A.P. Deauville for guidance on returns, refunds, or disposal of the items.
FAQs
What should I do if I purchased a recalled Power Stick deodorant?
Stop using the product immediately and contact A.P. Deauville for return instructions or refund.
Where were the recalled deodorants sold?
They were sold nationwide at Walmart, Dollar Tree and Amazon.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hindu
20 minutes ago
- The Hindu
Alzheimer's disease: Researchers find two cancer drugs reverse damaged gene behaviour in mice
A study that compared gene behaviour in Alzheimer's disease with that caused by 1,300 drugs approved for use in the US has found that a combination of two cancer drugs could slow the neurodegenerative disease in mice, indicating a promise in reversing symptoms in humans. Alzheimer's disease is an ageing-related disorder in which cognitive function steadily declines, affecting speech and memory, and eventually can interfere with everyday activities. Scientists at the University of California, San Francisco, and Gladstone Institutes in the US first saw how gene behaviour was affected in Alzheimer's disease in a single brain cell. The researchers then looked at 1,300 drugs approved by the US Food and Drug Administration (FDA) and which of them reversed the damage. The next stage of the study, published in the journal 'Cell', analysed electronic medical records of about 1.4 million patients and found that patients who took some of these drugs for treating conditions other than Alzheimer's disease were less likely to get the ageing-related neurological disorder. Testing the top two drug candidates -- 'letrozole' and 'irinotecan', both of which are cancer medications -- in a mouse model having Alzheimer's disease, the researchers found that brain degeneration was reduced and a restored ability to remember. Letrozole is usually prescribed for treating breast cancer, and irinotecan for colon and lung cancer. The combined effects of two drugs were found to reverse damaged gene behaviour in neurons and glia (a type of brain cells that surround and support neurons). Further, toxic clumps of proteins and brain degeneration -- hallmark features of Alzheimer's -- were found to be reduced and memory restored, the researchers said. The team added that out of 1,300 drugs, 86 reversed gene behaviour changes in one type of brain cell and 25 reversed them in other types. However, only 10 had been approved for use in humans by the FDA. "Thanks to all these existing data sources, we went from 1,300 drugs, to 86, to 10, to just five," said lead author Yaqiao Li, a postdoctoral scholar at Gladstone Institutes. "Alzheimer's disease comes with complex changes to the brain which has made it tough to study and treat, but our computational tools opened up the possibility of tackling the complexity directly," said co-senior author Marina Sirota, professor of paediatrics and an interim director at the University of California. Co-senior author Yadong Huang, director of the center for translational advancement at Gladstone Institutes, said, "Alzheimer's is likely the result of numerous alterations in many genes and proteins that, together, disrupt brain health." "This makes it very challenging for drug development -- which traditionally produces one drug for a single gene or protein that drives disease," Huang said. The electronic medical records analysed in the study came from the University of California's Health Data Warehouse, which includes anonymised health information on 1.4 million people over the age of 65.
Time of India
4 hours ago
- Time of India
Dubai pistachio chocolate spread linked to salmonella outbreak: What you need to know
A popular pistachio-cocoa spread sold in the US has been linked to a Salmonella outbreak, causing illness in several people, including one who was hospitalised. The spread, made by a Turkish company and sold at World Market stores, is now being recalled nationwide. Tired of too many ads? go ad free now Salmonella is a harmful bacterium that can cause stomach pain, diarrhoea, fever, and vomiting. It can be very serious, especially for young children, older adults, and people with weak immune systems Salmonella found in popular pistachio cocoa spread sold nationwide According to reports, on July 14, 2025, World Market and the FDA announced a recall after the Minnesota Department of Agriculture detected Salmonella during routine testing. The recall involves Emek Gıda's Spread Pistachio Cacao Cream with Kadayif, a pistachio-cocoa spread manufactured by a Turkish company and sold at World Market stores across more than 30 US states, including Alabama, California, Florida, Illinois, Minnesota, New York, Texas, Virginia, Washington, and Wisconsin. Source: The CDC later confirmed four cases of illness linked to this pistachio cream product, including one hospitalisation. Consumers who have purchased the affected 9.7 oz jars labeled with 'Dubai' are strongly advised not to consume the product. Salmonella is a harmful bacterium that can cause serious and sometimes fatal infections, especially in young children, the elderly, and individuals with weakened immune systems. What is Salmonella and why is it dangerous Salmonella is a common bacterial infection that affects the digestive system. It is often caused by consuming contaminated food or beverages. Symptoms include diarrhea, stomach cramps, fever, nausea, and vomiting. While many people recover without treatment, Salmonella infections can be severe, especially in young children, elderly individuals, and those with weakened immune systems. In serious cases, the infection can lead to hospitalisation or even life-threatening complications. Tired of too many ads? go ad free now This recent outbreak linked to the pistachio-cocoa spread has raised concerns about food safety standards and consumer awareness. Symptoms to watch for after consuming the Dubai chocolate spread If you or your family have consumed the recalled pistachio-cocoa spread, watch for symptoms such as diarrhea, abdominal pain, fever, and vomiting. These signs typically appear 6 hours to 6 days after infection. If symptoms are severe or persistent, especially in vulnerable groups like children or the elderly, seek medical attention immediately. Early diagnosis and treatment can help reduce complications and speed up recovery. What to do if you have a Salmonella infection If you suspect you have a Salmonella infection, contact your healthcare provider promptly. Diagnosis is typically confirmed through stool tests, and treatment may include hydration and, in some cases, antibiotics. It's also important to report your illness to local health departments to help track outbreaks and prevent further spread. Early medical intervention can prevent serious health outcomes. Also read|
Time of India
8 hours ago
- Time of India
Can cancer drugs treat Alzheimer's? New study thinks so
Alzheimer's disease, a progressive neurodegenerative disorder that primarily affects memory and cognitive functions, is the most common cause of dementia, accounting for 60-70% of dementia cases. As per Alzheimer's Association, in 2025, global Alzheimer's statistics indicate a significant prevalence of the disease, with projections estimating that over 7 million Americans will be living with Alzheimer's dementia. Globally, it is estimated that someone develops dementia every three seconds, and the number of people living with dementia is expected to reach 78 million by 2030. The progressive neurodegenerative disorder, long considered a therapeutic dead end, may soon find some hope of cure in an unlikely ally: cancer drugs. Recent research reveals that several oncology medications, originally designed to fight tumors, have shown promise in targeting key pathways of Alzheimer's disease (AD), from protein aggregation to neuroinflammation and metabolic dysfunction. Let's delve deeper into the newest discovery of the silver lining. The medical breakthrough: Scientists are exploring cancer drugs as a potential way to tackle Alzheimer's disease, given that the options for treatment are quite limited. As cases of Alzheimer's continue to rise in the U.S. and around the world due to an aging population, there still isn't a cure. Efforts to create new treatments that actually slow the disease's progression have mostly fallen short. Currently, only two drugs, Leqembi and Kisunla, are approved by the FDA to slow down early Alzheimer's, but their effectiveness is very limited. Many pharmaceutical companies have even stopped developing Alzheimer's drugs after unsuccessful trials, while others are experimenting with existing medications, including popular weight loss drugs. Researchers at the University of California, San Francisco, have taken a different approach. They searched through a database of over 1,300 various drugs, like antipsychotics and chemotherapy drugs, to find ones that could be repurposed for Alzheimer's treatment. Their study, published in the journal Cell , highlighted two cancer drugs that showed promise in reducing Alzheimer's risk. When tested together on mice, these drugs appeared to slow or even reverse Alzheimer's symptoms. One drug is typically used for breast cancer, and the other works against colon and lung cancer. Alzheimer's is known to cause significant changes in gene expression in the brain, which can disrupt brain function and lead to memory loss. From their database, fewer than 90 drugs successfully reversed markers related to Alzheimer's in human brain cells. Of these, five drugs seemed particularly effective in lowering Alzheimer's risk for actual patients, and the researchers focused on two FDA-approved cancer drugs to test in mice. According to the findings, letrozole, a breast cancer drug, appeared to influence gene expression in nerve cells, while irinotecan, used for colon and lung cancer, affected glial cells, which support the nervous system. Alzheimer's can damage nerve cells and trigger an overgrowth of glial cells, leading to brain inflammation. Interestingly, past studies have shown that breast cancer patients on letrozole had a lower chance of developing Alzheimer's, and colorectal cancer survivors treated with irinotecan also showed decreased risk, adding to the excitement around these findings. The groundbreaking findings: Researchers have been testing a combination of two cancer drugs in mice and found some promising results: the combo reversed brain degeneration and improved memory in mice showing signs of Alzheimer's. However, because what works in mice doesn't always work in humans, they plan to test these drugs in a clinical trial with Alzheimer's patients. Dr. Yadong Huang, a co-author of the study and a neurology professor at UCSF, noted the advantages of repurposing existing drugs: 'Developing a new drug can take hundreds of millions, or even billions, of dollars, and on average takes more than 10 years. For this repurposed drug, usually, it just takes two or three years, and then you can go to the clinical trial, and the cost is much, much lower.' Despite this progress, he acknowledged, as reported by NBC News, 'We still haven't generated or produced any very effective drugs that can really slow down dramatically the cognitive decline. ' Alzheimer's remains a complex disease, and its exact cause is still a mystery. Currently, it isn't clear why these cancer drugs might help with Alzheimer's. One idea is that the breast cancer drug reduces estrogen production, which controls many genes. Another theory is that the colon and lung cancer drug might reduce inflammation in the brain by stopping glial cells from multiplying. Dr. Melanie McReynolds, a biochemistry assistant professor at Pennsylvania State University, who wasn't involved in this study, added another angle. Her research suggests that another cancer drug can help Alzheimer's by regulating glucose metabolism, which is how cells generate energy. 'With aging, with stress, with diseases, that line of communication is disrupted,' she explained. She believes the drug combo could reverse metabolic decline, calling it 'the secret for contributing to better outcomes with Alzheimer's. ' What's ahead: Cancer drug repurposing opens a transformative chapter in Alzheimer's treatment, where repurposing anticancer agents allows researchers to exploit existing toxicity and pharmacokinetic data, potentially accelerating human testing and reducing development costs. While these findings are exciting, the potential side effects need to be carefully considered. Letrozole can cause hot flashes, and irinotecan may lead to severe diarrhea. 'These drugs have huge side effects, so you need to always balance and figure out whether those types of side effects would be amenable to somebody with Alzheimer's,' Sirota cautioned. 'It's not that it's a slam dunk.' Reduced risk of Alzheimer's disease linked to target protein for diabetes, as per a study
